United Therapeutics Partners with Former NFL Player Devon Still and His Daughter Leah to Launch “Braving NeuroBLASToma” in Honor of Childhood Cancer Awareness Month

Published on : Published by : BioBuzz Media

United Therapeutics Corporation (Nasdaq: UTHR) today announced it is joining forces with former NFL player Devon Still and his daughter Leah, a survivor of high-risk neuroblastoma, to launch the educational initiative “Braving NeuroBLASToma” shining a light on the rare cancer affecting immature nerve cells called neuroblasts.iv Neuroblastoma often develops in infants and children under the age of five, but the average age of diagnosis is between one and two years old.

United Therapeutics Announces FDA Acceptance of Tyvaso DPI™ New Drug Application For Priority Review

Published on : Published by : BioBuzz Media

United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review the New Drug Application (NDA) for Tyvaso DPI™ (inhaled treprostinil) for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). United Therapeutics expects the agency’s review to be complete in October 2021. FDA also indicated that they have not identified any potential review issues at this time.

United Therapeutics Announces Submission of Tyvaso DPI™ New Drug Application to FDA

Published on : Published by : BioBuzz Media

United Therapeutics Announces Submission of Tyvaso DPI™ New Drug Application to FDA SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., April 19, 2021 /PRNewswire/ — United Therapeutics Corporation (Nasdaq: UTHR) today announced the submission of a [….]

United Therapeutics Announces FDA Approval and Launch of Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

Published on : Published by : BioBuzz Media

United Therapeutics Announces FDA Approval and Launch of Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

United Therapeutics Announces Commercial Launch Of The Remunity® Pump For Remodulin® | United Therapeutics Corporation

Published on : Published by : BioBuzz Media

United Therapeutics Corporation (Nasdaq: UTHR) announced today that it has launched commercial sales of the innovative Remunity ® Pump for Remodulin ® for patients with pulmonary arterial hypertension (PAH). “We are excited to bring to market the first subcutaneous pump designed specifically for PAH patients,” said Beth Rhodes, Vice President, Global Supply Chain Alliance Management…

Top Life Science Employers in Maryland, 2020

Published on : Published by : Steven Surdez

The combination of a booming biotech market with an additional surge of hiring by vaccine and diagnostic companies in Maryland has resulted in record-low unemployment and competition for talent at an all-time high.